---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000048"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:10:55.831496+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aerovate appoints former Acceleron CEO Habib Dable to Board of Directors

## Summary
- Habib Dable appointed to Board effective July 10, 2023 as Class II director through 2026.
- Dable was President/CEO of Acceleron, which sold to Merck in 2021 for >$11B.
- He brings nearly 30 years of biopharma experience, including roles at Bayer and RA Capital.
- Dable will serve on the Compensation Committee alongside Iwicki and Katabi.
- Company continues advancing AV-101, inhaled imatinib, for pulmonary arterial hypertension.

## SEC filing metadata
- accession: 0001798749-23-000048
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000048/0001798749-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000048/tmb-20230710x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000048
- JSON: https://secwatch.observer/filing/0001798749-23-000048.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000048.txt

## Key facts
- Executive change
  Habib J. Dable was appointed as Director at Jade Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of July 10, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Habib J. Dable as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000048/0001798749-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.